Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Non-Current Liabilities (2022 - 2025)

Historic Total Non-Current Liabilities for Agios Pharmaceuticals (AGIO) over the last 8 years, with Q3 2025 value amounting to $101.3 million.

  • Agios Pharmaceuticals' Total Non-Current Liabilities fell 3822.8% to $101.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.3 million, marking a year-over-year decrease of 3822.8%. This contributed to the annual value of $121.4 million for FY2024, which is 286.53% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $101.3 million for Q3 2025, which was down 3822.8% from $101.6 million recorded in Q2 2025.
  • Agios Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $164.0 million during Q3 2024, with a 5-year trough of $88.1 million in Q1 2025.
  • Over the past 5 years, Agios Pharmaceuticals' median Total Non-Current Liabilities value was $119.8 million (recorded in 2023), while the average stood at $120.4 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 3748.73% in 2024, then plummeted by 3822.8% in 2025.
  • Agios Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $145.8 million in 2021, then decreased by 7.64% to $134.6 million in 2022, then dropped by 7.19% to $124.9 million in 2023, then fell by 2.87% to $121.4 million in 2024, then decreased by 16.54% to $101.3 million in 2025.
  • Its Total Non-Current Liabilities was $101.3 million in Q3 2025, compared to $101.6 million in Q2 2025 and $88.1 million in Q1 2025.